Results 11 to 20 of about 51,381 (340)

Will Short Peptides Revolutionize Chelation Therapy?

CHIMIA, 2022
It will soon be twenty years since the last chelating agent was clinically approved to be used against toxic metals. Even though metal poisoning has been known to humankind for centuries, only about a dozen compounds, all of which are small molecules ...
Michal S. Shoshan
doaj   +3 more sources

Pubertal Development in Girls with Beta Thalassaemia and Assessment of the Adequacy of Chelation Therapy: A Quasi-experimental Study [PDF]

Journal of Clinical and Diagnostic Research
Introduction: Beta thalassaemia is the most prevalent hereditary autosomal disorder, significantly impacting endocrine function during pubertal development. The pathology is rooted in the excessive deposition of iron in vital organs.
Rupali Modak, Amitava Pal, Shuvendu Das, Dilip Kumar Biswas   +3 more
doaj   +2 more sources

Chelation therapy.

The Western journal of medicine, 1975
This statement was prepared in response to a request made to the Clinical Pharmacology Service at the University of California, San Francisco to evaluate the potential therapeutic uses and the possible toxicities of chelation therapy. The question arose in regard to the use of ethylene tetraacetic acid (EDTA) in the treatment of atherosclerotic ...
P C, Carven, H F, Morrelli
openaire   +3 more sources

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. [PDF]

Cochrane Database Syst Rev, 2023
Geneen LJ, Dorée C, Estcourt LJ.
europepmc   +3 more sources

The trial to assess chelation therapy 2 (TACT2): Rationale and design. [PDF]

Am Heart J, 2022
Lamas GA, Anstrom KJ, Navas-Acien A, Boineau R, Kim H, Rosenberg Y, Stylianou M, Jones TLZ, Joubert BR, Santella RM, Escolar E, Aude YW, Fonseca V, Elliott T, Lewis EF, Farkouh ME, Nathan DM, Mon AC, Gosnell L, Newman JD, Mark DB, TACT2 Investigators.   +21 more
europepmc   +2 more sources

Iron Chelation Therapy With Deferasirox in Sickle Cell Disease With End-Stage Renal Disease. [PDF]

Cureus, 2022
Raj A, McGowan K, Knapp E, Zhao J, Shah S.   +4 more
europepmc   +3 more sources

Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study

Hematology, Transfusion and Cell Therapy, 2023
Introduction: Magnetic resonance imaging (MRI) T2* technique is used to assess iron overload in the heart, liver and pancreas of thalassaemic patients. Optimal iron chelation and expected tissue iron response rates remain under investigation.
Eduardo Cerello Chapchap, Murilo Marques Almeida Silva, Reijane Alves de Assis, Lucila Nassif Kerbauy, Michelli da Silva Diniz, Laércio Alberto Rosemberg, Sandra Regina Loggetto, Aderson da Silva Araujo, Antonio Fabron Junior, Monica Pinheiro de Almeida Verissimo, Giorgio Roberto Baldanzi, Breno Pannia Esposito, Fernando Tricta, Merula Emmanoel Anargyrou Steagall, Claudia Ângela Galleni Di Sessa Vellozo, Kleber Yotsumoto Fertrin, Ronaldo Hueb Baroni, Nelson Hamerschlak   +17 more
doaj   +1 more source

Assessment of iron chelation therapy adherence in patients with thalassemia major in Babylon Province

Journal of Applied Hematology, 2023
BACKGROUND: Thalassemia is severe public health problem in Iraq and other nearby countries, represents about 75% of all hemogloniopathy with prevalence and incidence 36/100.000 and 34/100.000 respectively.
Mohammed Ali Al-Jabory, Athmar Kadhim Gatea, Qusay Naser Hussein   +2 more
doaj   +1 more source

Blood-brain barrier transport kinetics of NOTA-modified proteins : the somatropin case [PDF]

, 2020
BACKGROUND: Chemical modifications such as PEG, polyamine and radiolabeling on proteins can alter their pharmacokinetic behaviour and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a
Bracke, Nathalie, De Spiegeleer, Bart, Janssens, Yorick, Maes, Alex, Sathekge, Mike, Tack, Liesa, Van De Wiele, Christophe, Wynendaele, Evelien   +7 more
core   +1 more source

Chelation therapy in children

Медицинский совет, 2016
Iron overload (RV) is a condition caused by excessive intake of iron, and in the absence of the specific mechanisms for its excretion - excessive accumulation in tissues and their subsequent lesion leading to functional organ failure [1].
M. V. Krasolnikova
doaj   +1 more source